ZhuZhou QianJin Pharmaceutical Co.,Ltd Stock

Equities

600479

CNE000001GX3

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
11.67 CNY -0.43% Intraday chart for ZhuZhou QianJin Pharmaceutical Co.,Ltd +7.66% +8.36%
Sales 2022 4.03B 556M Sales 2023 3.8B 524M Capitalization 4.62B 638M
Net income 2022 304M 41.96M Net income 2023 320M 44.17M EV / Sales 2022 0.58 x
Net cash position 2022 1.79B 247M Net cash position 2023 1.88B 260M EV / Sales 2023 0.72 x
P/E ratio 2022
13.5 x
P/E ratio 2023
14.2 x
Employees 5,335
Yield 2022
3.65%
Yield 2023
3.25%
Free-Float 67.37%
More Fundamentals * Assessed data
Dynamic Chart
Qianjin Pharma Unit Gets Nod for Supplemental New Drug Application for Teralithe Biosimilar MT
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announced that it has received CNY 50 million in funding from a group of investors CI
Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announces tranche update CI
Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announced that it expects to receive CNY 310 million in funding from ZhuZhou QianJin Pharmaceutical Co.,Ltd, Capstone Strategic, Inc. CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding from ZhuZhou QianJin Pharmaceutical Co.,Ltd CI
ZhuZhou QianJin Pharma Gets Nod to Register Blood Circulation Drug in Canada MT
QianJin Pharma’s Product Selected Among Top 100 Evidenced-Based Traditional Chinese Medicines MT
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhuzhou Qianjin Pharma's Unit Gets Nod for Chronic Hepatitis B Drug MT
ZhuZhou QianJin Pharma Promotes Vice Chairman to Chairman MT
Zhuzhou QianJin Pharmaceutical's Chairman Resigns; Shares Rose 5% MT
More news
1 day-0.43%
1 week+7.66%
Current month+8.06%
1 month+9.68%
3 months+21.31%
6 months+14.75%
Current year+8.36%
More quotes
1 week
11.12
Extreme 11.12
11.83
1 month
10.41
Extreme 10.41
11.83
Current year
8.59
Extreme 8.59
11.83
1 year
8.59
Extreme 8.59
15.07
3 years
7.96
Extreme 7.96
16.00
5 years
7.96
Extreme 7.96
16.00
10 years
7.33
Extreme 7.33
26.43
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 23-06-19
Chairman 47 18-03-29
Chairman 53 15-06-30
Members of the board TitleAgeSince
Director/Board Member 56 05-11-17
Director/Board Member 58 20-11-15
Chairman 53 15-06-30
More insiders
Date Price Change Volume
24-04-23 11.67 -0.43% 8,718,600
24-04-22 11.72 +2.09% 12,035,560
24-04-19 11.48 +1.59% 8,536,861
24-04-18 11.3 +1.25% 9,645,221
24-04-17 11.16 +2.95% 7,891,331

End-of-day quote Shanghai S.E., April 22, 2024

More quotes
ZhuZhou QianJin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production, wholesaling and retailing of drugs. The Company's main products include tablets, granules, pills, hard capsules, syrups, herbs, vinum and gels, among others. The company is also involved in the businesses of cultural entertainment, logistics and distribution, as well as the provision of hygienic products.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 600479 Stock